Dr. Chan specializes in the surgical and medical treatment of ovarian and other pelvic cancers at CPMC. He is board certified in gynecologic oncology, and obstetrics and gynecology. He is investigating new treatments for gynecologic cancers, including targeted biologic therapies, and exploring the role of tumor-initiating cells in ovarian cancer. A clinician and surgeon, Dr. Chan is a principal investigator of studies assessing the treatment and health outcomes of ovarian and uterine cancer patients.
Sutter Health Research Enterprise
1501 Trousdale Drive
Burlingame, CA, 94010
(415) 751-1847
ChanJK@Sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (NRG GY023)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting
Metastatic (NRG GY018)
Testing Addition of Immunotherapy Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting
Metastatic (Sutro STRO-002-GM1)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic or Locally Advanced (Agenus GOG 3028) (Temp Enrollment Hold)
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Not Recruiting